This Case study demonstrates the importance of the cell processing and cell culture workflow steps required to improve and develop cell therapies whilst meeting regulatory compliance, increasing speed and reducing costs.
The rapid growth of the cell therapy market continues to drive – and require – improvements in the development and manufacturing workflow to increase speed, reduce cost, and meet regulatory compliance. In particular, cell therapy developers have focused on reducing the risk of contamination during the cell processing and cell culture workflow steps, as contamination risk has been a regulatory focus.
Download the full Case Study to find out more.
This Case Study has been produced in partnership with GeminiBio.